LRG1 is an independent prognostic factor for endometrial carcinoma
LRG1 is an independent prognostic factor for endometrial carcinoma
复制标题
LRG1是子宫内膜癌的独立预后因素。
DOI：
10.1007/s13277-014-1953-6
复制
发表时间：
2014-07-01
期刊：
影响因子：
--
通讯作者：
Teng, Yin-Cheng
中科院分区：
文献类型：
--
作者：
Wen, Shan-Yun;Zhang, Li-Na;Teng, Yin-Cheng
子宫内膜癌（EC）是最常见的女性恶性肿瘤之一。具有高危因素的患者可能预后较差。因此，迫切需要找到一种新的分子来更准确地预测患者的生存情况。富含亮氨酸的α2-糖蛋白1（LRG1）是富含亮氨酸重复序列家族之一，与癌症转移和不良预后密切相关。 LRG1 在 EC 中的生物学功能和表达水平仍然不清楚。在本研究中，通过对 242 名 EC 患者组织进行免疫组织化学分析，我们发现测试队列（133 名患者）和验证队列（109 名患者）中 LRG1 表达与分期和淋巴转移相关。此外，为了研究 LRG1 在子宫内膜癌中的预后价值，我们使用 Cox 比例风险回归分析了变量与总生存率之间的相关性。结果表明LRG1是子宫内膜癌患者总生存期的独立预后因素。为了进一步评估LRG1在子宫内膜癌中的预后效率，我们通过logistic回归比较了LRG1在子宫内膜癌预后中的敏感性和特异性。结果表明，LRG1与其他临床病理危险因素联合是比单独临床病理危险因素或其组合更强的预后模型。因此，LRG1 在指导子宫内膜癌患者的个体治疗方面具有潜在的临床价值。
Endometrial cancer (EC) is one of the most common female malignancies. The patients with high-risk factors may have poor prognosis. Therefore, there is an urgent need to find a new molecule to more accurately predict survival of patients. Leucine-rich-alpha-2-glycoprotein1 (LRG1), one of leucine-rich repeat family, was closely associated with cancer metastasis and poor prognosis. The biological functions and the expression level of LRG1 remain obscure in EC. In this study, by immunohistochemical analysis of 242 EC patient tissues, we found that LRG1 expression was associated with stage and lymphatic metastasis in both test cohort (133 patients) and validation cohort (109 patients). Furthermore, to investigate the prognostic value of LRG1 in endometrial carcinoma, we analyzed the correlation between variables and overall survival with Cox proportional hazard regression. The result showed that LRG1 was an independent prognostic factor for overall survival of endometrial carcinoma patients. To further evaluate the prognostic efficiency of LRG1 in endometrial carcinoma, we compared the sensitivity and specificity of LRG1 in endometrial carcinoma prognosis by logistic regression. The result showed that LRG1 combining with other clinicopathological risk factors was a stronger prognostic model than clinicopathological risk factors alone or their combination. Thus, LRG1 potentially offered clinical value in directing personal treatment for endometrial carcinoma patients.